Презентация на тему Typical / conventional antipsychotics

tachy, incontinence)
Confusion (altered consciousness up to coma, dysphagia, mutism)
Raised

CK
Misc (incontinence, dysphagia)

Treat in ICU if severe:

Bromocriptine 2.5mg BD + dantrolene 50mg IV

Prognosis:

30% will have it again upon rechallenge with antipsychotics
Use low potency agent, wait 14 days, monitor carefully

(NMS)

After symptom resolution
Some suggest to wait for at least

2 weeks before resuming
Use lowest effective dose
Avoid high potency agents
Consider atypical antipsychotics
However, NMS has been reported from patients taking clozapine, risperidone, olanzapine and quetiapine

clozapine and ziprasidone
ii. Drugs have quinidine- like effects –

QT prolongation, ST
depression, increased HR
iii. Get baseline EKG in patients >50 years of age
iv. Do serum K+
iv. D/C medication if QTc>500 msec

Dermatological
Increased photosensitivity – especially with chlorpromazine
ii. Pigmentation changes with chlorpromazine
iii. Rash – seen within first eight weeks

IM chlorpromazine abscesses

decreases dopamine inhibition of prolactin
Results in galactorrhea, amenorrhea, loss

of libido
Managed with bromocriptine
Sedation
Administer once daily at bedtime
Seizures
Haloperidol has a lower risk of seizures
Anticonvulsants (beware or possible interaction with antipsychotic)

Not dose related
iii. Usually in patients

Can cause cholestatic jaundice – usually in first month

1. Resolves with D/C of drug without damage
2. Most commonly seen with chlorpromazine (0.1-0.5%)

Ophthalmic effects
i. Blurred vision or narrow angle glaucoma secondary to
anticholinergic effects (see anticholindergic side effects above)
ii. Corneal and lens changes can occur with phenothiazines,
especially chlorpromazine and quetiapine

D2 > D1

Haloperidol: D2 > D1 = D4 >

α1 > 5-HT2

Clozapine: D4 = α1 > 5-HT2 > D2 = D1

D2 receptors
Chlorpromazine and thioridazine
block α1 adrenoceptors more potently than

D2 receptors
block serotonin 5-HT2 receptors relatively strongly
affinity for D1 receptors is relatively weak
Haloperidol
acts mainly on D2 receptors
some effect on 5-HT2 and α1 receptors
negligible effects on D1 receptors
Pimozide and amisulpride†
act almost exclusively on D2 receptors

well

Glutamate antagonists can help with negative symptoms

Schizophrenia

likely affects a host of systems perhaps by
disturbing a fundamental balance among neurotransmitters

(Zyprexa®), Zypadhera
Clozapine (Clozaril®)
Aripiprazole (Abilify®), Xeplion

receptors
Seem to be a little more selective, targeting the

intended pathway to a larger degree than the others
Also block or partially block serotonin receptors (particularly 5HT2A, C and 5HT1A receptors)
Aripiprazole: dopamine partial agonist (novel mechanism)
Partial agonist effects at D2 and 5-HT1A receptors

of D2 and serotonin 2A receptors, but they can

affect many other types of receptors.
Atypical antipsychotics: 
D2 receptor blockade of postsynaptic in the mesolimbic pathway reduce positive symptoms
Enhanced dopamine release and 5-HT2A receptor blockade in the mesocortical pathway reduce negative symptoms
other receptor-binding properties may contribute to efficacy in treating cognitive symptoms, aggressive symptoms and depression in schizophrenia

5-HT2, α1, and histamine H1 receptors than to either

D2 or D1 receptors
Risperidone
about equally potent in blocking D2 and 5-HT2 receptors
Olanzapine
more potent as an antagonist of 5-HT2 receptors
lesser potency at D1, D2, and α1 receptors
Quetiapine
lower-potency compound with relatively similar antagonism of 5-HT2, D2, α1, and α2 receptors

symptoms)
better compliance
Evidence?
trials have been quite small and involved patients

previously heavily treated and somewhat ‘resistant’
trials have tended to show equivalent efficacy and better side effect profiles with newer drugs
head to head trials claimed superiority of olanzapine over risperidone (but company sponsored and controversial); some “parallel publications”
Costs
Much higher with new drugs (10-40 times higher)

chance / year of converting to Type 2 diabetes
Prediabetes

plus olanzapine has a 6-fold increased risk of conversion
If olanzapine is stopped 70% will revert back to prediabetes

increased risk of stroke when used for behavioural control

in dementia
Risperidone 3.3% vs 1.2% for placebo
Olanzapine 1.3% vs 0.4% for placebo
However, large observational database studies
Show no increased risk of stroke compared with typical antipsychotics or untreated dementia patients

as dopamine blockade
As a group have less chance of

extrapyramidal side effects
Most have weight gain and insulin resistance as a side effect (except perhaps aripiprazole and maybe amisulpride)
May be associated with stroke when used for behavioural control in dementia (?!)
Many have idiosyncratic toxicities

(clozapine, risperidone, olanzapine) but not all atypicals when compared

with typicals
At least as effective as typicals for positive symptoms
May be more efficacious for negative and cognitive symptoms (still under debate)

therapeutic doses
Except clozapine
Most effective antipsychotic
For resistant schizophrenia
2nd line due

to life-threatening side effect

recommendations
Atypical antipsychotics considered when choosing 1st line treatment of

newly diagnosed schizophrenia
Treatment option of choice for managing acute schizophrenic episode
Considered when suffering unacceptable adverse effects from a conventional antipsychotic
Changing to an atypical not necessary if typical controls symptoms adequately and no unacceptable adverse effects

reducing symptoms and preventing relapse
Use of clozapine effectively reduce

suicide risk
1% risk of potentially fatal agranulocytosis
Acute pronounced leukopenia with great reduction in number of neutrophil
NICE (The National Institute for Health and Care Excellence) recommendations
Clozapine should be introduced if schizophrenia is inadequately controlled despite sequential use of 2 or more antipsychotic (one of which should be an atypical) each for at least 6-8 weeks)

G. Stille at Wander Pharmaceuticals in Bern, Switzerland, in

the early 1960s worked to refute that EPS and antipsychotic efficacy were linked.
Their work led to the introduction of Clozapine, an antipsychotic with no EPS.”
Clozapine was briefly marketed and quickly withdrawn for two reasons:
The embarrassment of not having any EPS, and
Agranulocytosis

to antipsychotics that have an affinity for DA D2

receptors. This has lead researchers to believe that there are other Dopamine receptors that may contribute to the cause of schizophrenia.
The DA D4 subtype has also been implicated in the illness.
The DA D4 is of special interest because of its concentration in the hippocampus and the cerebral cortex. It is through the D2 and the D4 receptors that Clozapine exerts its affects.

Heinrichs, R. W., (2001). In Search of Madness: Schizophrenia and Neuroscience. Oxford University Press: New York.

will not bind to any Dopamine receptor, it is

selective, it has an affinity for the D4 receptor subtype.

however, it is believed that Clozapine selectively antagonizes dopamine

D1 and D4 receptors, serotonin 5-HT2 receptors and others.
Atypical antipsychotics, like Clozapine, are distinguished by their relatively low affinity for the DA D2 receptor subtype and its high affinity for the DA D4 receptor subtype and the 5-HT2 receptor subtype.
Clozapine may be able to permit more normal dopaminergic function in the anterior pituitary, the mesostriatal, mesolimbic and mesocortical regions

patients is approximately 900mg per day, but the regular

range 400-600 mg/d .
To minimize side effects, the initial dose of Clozapine may start of low and progressively increase to 200mg taken three times per day.
Clozapine is not a cure for schizophrenia, rather, it is used to relieve the symptoms of the disease. Therefore, the use of anti-psychotics is life-long to ensure that the symptoms are controlled.
The patient may decide to discontinue the use of Clozapine due to its side effects and is usually placed on a less potent antipsychotic.
The discontinuation of all anti-psychotics will cause a relapse of positive and negative symptoms.

differential blood count normal before starting
Monitor counts week for

18 weeks, then at least 2 weeks after 1 year
At least 4 weeks after count stable for 1 year (for 4 more weeks after discontinuation)
If leucocyte count < 3000/mm3, or if ANC (Absolute Neutrophil Count) < 1500/mm3, discontinue immediately and refer to hematologist
Patient should report immediately symptoms of infection, esp. flu-like illness (fever, sore throat)

in first 2 months
CSM (Committee on Safety of Medicines(recommendations
Physical

exam and medical history before starting
Persistent tachycardia esp. in first 2 weeks should prompt observation for cardiomyopathy
If myocarditis or cardiomyopathy, stop clozapine
Inform patients for unexplained fatigue, dyspnea, tachypnea, chest pain, paipitation and ask them to report these signs and symptoms immediately

drugs
Caution
Seizure disorders
Diabetes

with clozapine: differentiation from other atypical antipsychotics. Am J

Psychiatry. 2004 Sep;161(9):1620-5
Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.
OBJECTIVE: Clozapine, the prototype of atypical antipsychotics, remains unique in its efficacy in the treatment of refractory schizophrenia. Its affinity for dopamine D(4) receptors, serotonin 5-HT(2A) receptor antagonism, effects on the noradrenergic system, and its relatively moderate occupancy of D(2) receptors are unlikely to be the critical mechanism underlying its efficacy. In an attempt to elucidate the molecular/synaptic mechanism underlying clozapine's distinctiveness in refractory schizophrenia, the authors studied the in vivo D(1) and D(2) receptor profile of clozapine compared with other atypical antipsychotics.
RESULTS: The ratio of striatal D(1)/D(2) occupancy was significantly higher for clozapine (0.88) relative to olanzapine (0.54), quetiapine (0.41), or risperidone (0.31).

CONCLUSIONS: Among the atypical antipsychotics, clozapine appears to have a simultaneous and equivalent occupancy of dopamine D(1) and D(2) receptors. Whether its effect on D(1) receptors represents agonism or antagonism is not yet clear, as this issue is still unresolved in the preclinical arena. This distinctive effect on D(1)/D(2) receptors may be responsible for clozapine's unique effectiveness in patients with schizophrenia refractory to other typical and atypical antipsychotics.

Dopamine Receptors and Clozapine

with clozapine: differentiation from other atypical antipsychotics.
Tauscher J, Hussain

T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.

OBJECTIVE: Clozapine, the prototype of atypical antipsychotics, remains unique in its efficacy in the treatment of refractory schizophrenia. Its affinity for dopamine D(4) receptors, serotonin 5-HT(2A) receptor antagonism, effects on the noradrenergic system, and its relatively moderate occupancy of D(2) receptors are unlikely to be the critical mechanism underlying its efficacy. In an attempt to elucidate the molecular/synaptic mechanism underlying clozapine's distinctiveness in refractory schizophrenia, the authors studied the in vivo D(1) and D(2) receptor profile of clozapine compared with other atypical antipsychotics.
RESULTS: The ratio of striatal D(1)/D(2) occupancy was significantly higher for clozapine (0.88) relative to olanzapine (0.54), quetiapine (0.41), or risperidone (0.31).

CONCLUSIONS: Among the atypical antipsychotics, clozapine appears to have a simultaneous and equivalent occupancy of dopamine D(1) and D(2) receptors. Whether its effect on D(1) receptors represents agonism or antagonism is not yet clear, as this issue is still unresolved in the preclinical arena. This distinctive effect on D(1)/D(2) receptors may be responsible for clozapine's unique effectiveness in patients with schizophrenia refractory to other typical and atypical antipsychotics.

Am J Psychiatry. 2004 Sep;161(9):1620-5

Dopamine Receptors and Clozapine

atypical antipsychotic due to its elevated effects over other

“atypical” antipsychotics.
Patients do not experience extrapyramidal symptoms (EPS)
Used for treatment-resistant patients that have not responded to any other medication.
Has been shown to have some effectiveness in the treatment of negative symptoms.

There is a high correlation between patients who take this medication and the development of Agranulocytosis.
Clozapine costs more than typical anti-psychotics, however, the cost is relatively the same for atypical antipsychotics
The effective dose of Clozapine is higher than other atypical antipsychotics.
Tends to work more effectively in younger patients (20s) than older patients (30s).

ADVANTAGES

DISADVANTAGES

treatment?
There is some controversy surrounding this drug.
The debate is

over when this drug should be used. Many say that due to the increased risk of attaining Agranulocytosis (which can be fatal is not detected) this drug should be used only if the individual is un responsive to other drugs. However, there has been findings that Clozapine is significantly more affective if administered to the patient at a younger age.
Is this treatment appropriate for every patient?
No
Typically Clozapine is used on schizophrenic patients that are treatment-refractory or unresponsive to other medications.

atypicals
Risperidone (Risperdal Quicklet®)
Olanzapine (Zyprexa Zydis®)
Carefully peel off packing, allow

tablet to dissolve on tongue and swallow
Do not break the tablet
Some may be dispersed in fluids (consult manufacturer literature)
Solutions available for
1 typical
Haloperidol (Haldol® drops)
1 atypical
Risperidone (Risperdal® solution)
Very concentrated, avoid from contact with skin (dermatitis)

decanoate (Modecate®)
Flupenthixol (Fluanxol®)
Zuclopenthixol (Clopixol Depot®)
3 atypical
Risperidone (Risperdal Consta®)
Zyprexa (Zypadhera®)
Xeplion

( Aripiprizol ®)
Used for chronic illness and history of noncompliance
Trial of oral meds first to assess tolerability

side effect profile
Atypical antipsychotics may be appropriate if
Adverse

effect is a particular concern
Additional benefits for negative and cognitive symptoms required
Clozapine
2nd line treatment when other agents are ineffective or not tolerated

combativeness, anxiety, tension and aggression
Normalization of sleep and eating

habits
First 2-3 weeks
Increased socialization, improvement in self-care
6-8 weeks
Improvement in formal thought disorder

average effective dose
Stabilization phase
Dose titration within the therapeutic range
Maintenance

phase
Therapy should be continued for at least 12 months after remission of 1st episode
Good treatment responders should be treated for at least 5 years
Continuous lifetime maintenance required in the majority of patients to prevent relapse
Lowest effective and tolerable dose

global impairment and psychosis
Schizophrenic patients are prone to BZD

abuse
Limit use to short trials (2-4 weeks) for management of severe agitation and anxiety
Lithium
Limited role in schizophrenia monotherapy
Improve psychosis, depression, excitement, and irritability when used with antipsychotic in some studies

antipsychotic
Alters metabolism of antipsychotic
NOT to be used with clozapine

(risk of agranulocytosis)
Valproate
Concurrent administration with risperidone and olanzapine resulted in early psychotic improvement in recent investigation
Propranolol
Research showed improvement in chronic aggression
Treat aggression or enhance antipsychotic response
Reasonable trial −240mg/day